Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yannan Zhou

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Journal of the American Chemical Society|December 10, 2016
Pressure-Driven Cooperative Spin-Crossover, Large-Volume Collapse, and Semiconductor-to-Metal Transition in Manganese(II) Honeycomb LatticesYonggang Wang, Zhengyang Zhou, Ting Wen, et al.
Frontiers in Pharmacology|October 24, 2022
Pharmacokinetics and safety of the two oral cefaclor formulations in healthy chinese subjects in the fasting and postprandial statesXinyao Qu, Qiaohuan Deng, Ying Li, et al.
Nature Communications|May 17, 2018
Emergent superconductivity in an iron-based honeycomb lattice initiated by pressure-driven spin-crossoverYonggang Wang, Jianjun Ying, Zhengyang Zhou, et al.
Expert Opinion on Biological Therapy|October 5, 2021
A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjectsGuangwen Liu, Zhongnan Xu, Wei Yang, et al.
Expert Opinion on Investigational Drugs|February 9, 2023
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjectsYanli Wang, Jinling Xue, Zhengjie Su, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 12, 2022
A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjectsZhengzhi Liu, Zhenyue Gao, Wei Yang, et al.
International Immunopharmacology|April 23, 2022
A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjectsZhongnan Xu, Yanli Wang, Zhengzhi Liu, et al.
Expert Review of Clinical Pharmacology|March 8, 2023
Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trialZhongnan Xu, Zhengzhi Liu, Yanli Wang, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|April 21, 2024
Pharmacokinetics and safety of a new generic lurasidone: a phase I bioequivalence study in healthy Chinese subjectsZhengzhi Liu, Jinling Xue, Qiaohuan Deng, et al.
Expert Opinion on Investigational Drugs|April 15, 2022
A randomized, open-label, single-dose, two-cycle crossover study to evaluate the bioequivalence and safety of lenvatinib and Lenvima® in Chinese healthy subjectsZhongnan Xu, Yanli Wang, Guangwen Liu, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Journal of the American Chemical Society|December 10, 2016
Pressure-Driven Cooperative Spin-Crossover, Large-Volume Collapse, and Semiconductor-to-Metal Transition in Manganese(II) Honeycomb LatticesYonggang Wang, Zhengyang Zhou, Ting Wen, et al.
Frontiers in Pharmacology|October 24, 2022
Pharmacokinetics and safety of the two oral cefaclor formulations in healthy chinese subjects in the fasting and postprandial statesXinyao Qu, Qiaohuan Deng, Ying Li, et al.
Nature Communications|May 17, 2018
Emergent superconductivity in an iron-based honeycomb lattice initiated by pressure-driven spin-crossoverYonggang Wang, Jianjun Ying, Zhengyang Zhou, et al.
Expert Opinion on Biological Therapy|October 5, 2021
A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjectsGuangwen Liu, Zhongnan Xu, Wei Yang, et al.
Expert Opinion on Investigational Drugs|February 9, 2023
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjectsYanli Wang, Jinling Xue, Zhengjie Su, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 12, 2022
A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjectsZhengzhi Liu, Zhenyue Gao, Wei Yang, et al.
International Immunopharmacology|April 23, 2022
A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjectsZhongnan Xu, Yanli Wang, Zhengzhi Liu, et al.
Expert Review of Clinical Pharmacology|March 8, 2023
Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trialZhongnan Xu, Zhengzhi Liu, Yanli Wang, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|April 21, 2024
Pharmacokinetics and safety of a new generic lurasidone: a phase I bioequivalence study in healthy Chinese subjectsZhengzhi Liu, Jinling Xue, Qiaohuan Deng, et al.
Expert Opinion on Investigational Drugs|April 15, 2022
A randomized, open-label, single-dose, two-cycle crossover study to evaluate the bioequivalence and safety of lenvatinib and Lenvima® in Chinese healthy subjectsZhongnan Xu, Yanli Wang, Guangwen Liu, et al.
Pageof 7